Samantha Murphy

Samantha (Sam) Murphy is supporting the organization’s financing and business objectives, including fundraising efforts, portfolio review, and partnership strategy. Previously, she served as Co-founder and Vice President, Corporate Development of Lupa Bio, Inc., a start-up biotechnology company developing a novel anti-inflammatory compound for therapeutics. Dr. Murphy also served as Associate Director and Interim Head of Business Development and Alliance Management at Arcturus Therapeutics Ltd., where she supported the organization’s transition from private to public, provided strategy and program analysis to the executive management team, and managed a portfolio of strategic partners, including Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and the Cystic Fibrosis Foundation. Prior to her tenure at Arcturus, Samantha led the Nucleic Acid Medicine Group at Kyowa Kirin Pharmaceutical Research, Inc., a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd., and was responsible for advancement of multiple preclinical programs with a focus on autoimmune diseases. Dr. Murphy has a PhD in Biology from the University of California San Diego and performed her graduate studies at the Salk Institute for Biological Studies with Dr. Inder Verma, American Cancer Society Professor, and in collaboration with Dr. Ron Evans, Albert Lasker Award for Basic Medical Research Recipient.